ACE Technology Guidances

ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 27 Jul 2021
Last Updated on 17 Aug 2021
A- A+
Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has recommended:
  • Dacomitinib 15 mg, 30 mg and 45 mg tablets for treating locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer.

Subsidy status

Dacomitinib 15 mg, 30 mg and 45 mg tablets are recommended for inclusion on the MOH Standard Drug List (SDL) with effect from 3 August 2021.


Dacomitinib for treating EGFR mutation-positive NSCLC (17 Aug 2021) Dacomitinib for treating EGFR mutation-positive NSCLC PES (27 Jul 2021)